Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
0.9000
+0.1752 (24.17%)
At close: Apr 23, 2025, 4:00 PM
0.9000
0.00 (0.00%)
After-hours: Apr 23, 2025, 4:07 PM EDT
Sutro Biopharma Revenue
In the year 2024, Sutro Biopharma had annual revenue of $62.04M, down -59.64%. Sutro Biopharma had revenue of $14.81M in the quarter ending December 31, 2024, a decrease of -86.98%.
Revenue (ttm)
$62.04M
Revenue Growth
-59.64%
P/S Ratio
1.11
Revenue / Employee
$200,139
Employees
310
Market Cap
75.40M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
STRO News
- 5 weeks ago - Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - GlobeNewsWire
- 5 weeks ago - Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline - Benzinga
- 5 weeks ago - Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights - GlobeNewsWire
- 5 weeks ago - Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline - GlobeNewsWire
- 7 weeks ago - Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless - Seeking Alpha
- 5 months ago - Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire